Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 13,632 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Breast Carcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Triple-Negative Breast Carcinoma, Refractory Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Serous Adenocarcinoma, Refractory Primary Peritoneal Serous Adenocarcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable High Grade Fallopian Tube Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Primary Peritoneal Serous Adenocarcinoma
Interventions: Olaparib, Onalespib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 2 more

Conditions: Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma, Rhabdomyosarcoma, Ewing Sarcoma
Interventions: LN-145/LN-144; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 6 Months to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • St. Petersburg, Florida • New Brunswick, New Jersey + 2 more

Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions: Depletion of CD3/CD19 in an autologous stem cell transplant; Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: 8 Years to 25 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Port Wine Stain, Nevus of Ota, Tattoos, Scars, Acne, Hypertrichosis, Sebaceous Gland Diseases
Interventions: Optical Clearing; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Irvine, California

Conditions: Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions: tamoxifen citrate, busulfan, thiotepa, melphalan, aldesleukin, sargramostim, peripheral blood stem cell transplantation, radiation therapy; Drug · Biological · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 19 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Psoriasis
Interventions: Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 11 more

Conditions: Pressure Injury, Venous Ulcer, Necrotizing Soft Tissue Infection, Diabetic Ulcers, Draining Wound
Interventions: MicroMatrix® Flex, MicroMatrix® UBM Particulate, Cytal® Wound Matrix 2-Layer; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Lake Success, New York

Conditions: Stage IB Breast Cancer, Stage II Breast Cancer
Interventions: regional nodal XRT, chestwall XRT, WBI; Radiation
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 1,636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 489
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 356 more

Conditions: Rosacea
Interventions: Brimonidine; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Fort Smith, Arkansas • Newport Beach, California • Sacramento, California + 9 more

Conditions: Psoriasis, Cardiovascular Disease
Interventions: Adalimumab; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 9
States / cities: Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more

Conditions: Triple Negative Breast Cancer
Interventions: Temsirolimus, Cisplatin, Erlotinib; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Cancer, Prostate Cancer, Lung Cancer
Interventions: Educational materials, educational materials, plus patient navigation; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Foot Ulcer, Venous Ulcer
Interventions: Low Frequency, Low Intensity Ultrasound, Sham Applicator; Device
Lead sponsor: Drexel University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Insomnia, Depression
Interventions: Digital Insomnia Program, Digital Mental Health Program, Psychoeducation; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Breast Cancer
Interventions: Exercise training; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Malignant Melanoma
Interventions: Acitretin, Vemurafenib; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetic Foot Ulcer
Interventions: NOX1416 and SOC, SOC (Standard of care); Drug · Procedure
Lead sponsor: NOxy Health Products, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Coral Gables, Florida + 9 more

Conditions: Breast Cancer, Breast Cancer Metastatic
Interventions: Educational Brochure; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: surgery, therapy, radiation therapy; Procedure · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 48 Years to 120 Years · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetic Foot Ulcers, Osteomyelitis
Interventions: DFU; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Melanoma
Interventions: Anti-CD137 (4-1BB) (BMS-663513); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Park Ridge, Illinois + 7 more

Conditions: Breast Cancer
Interventions: pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 3,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2027
U.S. locations: 539
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more

Conditions: Breast Cancer
Interventions: IGRT for prone partial breast irradiation (PBI); Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Carcinoma, Breast Ductal Carcinoma in Situ
Interventions: Patient Navigation, Questionnaire; Behavioral · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

Optical Clearing of the Skin in Conjunction With Laser Treatments

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Study of Secukinumab With 2 mL Pre-filled Syringes

MicroMatrix® Flex in Tunneling Wounds

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Mirvaso in Use Study

Vascular Inflammation in Psoriasis - Extension Study

Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial

Enhanced Ultrasound Treatment of Chronic Wounds With Monitoring of Healing and Quality of Life Outcomes

Evaluating the Impact of Digital Behavioral Interventions to Address Insomnia and Depression in Breast Cancer Survivors Using an Adaptive Design

All-extremity Exercise During Breast Cancer Chemotherapy

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers

Nutrition Awareness Among Women With Non-Metastatic Breast Cancer

Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer

UT Southwestern Diabetic Foot Ulcers (DFU) and Osteomyelitis (DFO) Recruitment Database, Data and Tissue Repository

Phase II, 2nd Line Melanoma - RAND Monotherapy

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Image Guided Radiotherapy (IGRT) for Prone Partial Breast Irradiation

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care